Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 2/2013

01.02.2013 | Endocrine Tumors

What Is the Best Definitive Treatment for Graves’ Disease? A Systematic Review of the Existing Literature

verfasst von: Bradley M. Genovese, MD, Salem I. Noureldine, MD, Elizabeth M. Gleeson, BS, MPH, Ralph P. Tufano, MD, FACS, Emad Kandil, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists for Graves’ disease (GD) include any of the following modalities: 131I therapy, antithyroid medication, or thyroidectomy. No in-depth analysis has been performed comparing the treatment options, even though a single treatment option seems to be universally accepted.

Methods

A systematic review of the literature was performed to examine contemporary literature between 2001 and 2011 evaluating the management options of GD. We compiled retrospective and prospective studies analyzing surgery and radioactive iodine. Outcomes of interest included postoperative hypothyroidism, euthyroidism, and persistent or recurrent hyperthyroidism without supplementation. Success was defined as postoperative euthyroidism or hypothyroidism. Failure was defined as persistent or recurrent hyperthyroidism.

Results

Of the 14,245 patients, 4,546 underwent surgery [3,158 patients had subtotal thyroidectomy (STT) and 1,388 had total thyroidectomy (TT)] and 9,699 had radioactive iodine. The radioactive iodine group consisted of 2,383 patients receiving 1–10 mCi, 1,558 patients receiving 11–15 mCi, 516 patients receiving >15 mCi, and 5,242 patients receiving an unspecified amount. Surgery was found to be 3.44 times more likely to be successful than radioactive iodine (p < 0.001). STT and TT were found to be 2.33 and 94.45 times more likely to be successful than radioactive iodine (p < 0.001), respectively.

Conclusions

On the basis of the outcomes analyzed, surgery appears to be the most successful in the management of GD, with TT being the preferred surgical option.
Literatur
1.
Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24:802–35.PubMedCrossRef
2.
Hegedüs L. Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355–71.PubMedCrossRef
3.
4.
Abraham-Nordling M, Wallin G, Träisk F, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol. 2010;163:651–7.PubMedCrossRef
5.
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–9.PubMedCrossRef
6.
Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263–77.PubMed
7.
Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–7.PubMedCrossRef
8.
Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17:456–520.PubMed
9.
Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.PubMedCrossRef
10.
Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf). 1998;49:451–7.CrossRef
11.
Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Scottish Automated Follow-up Register Group. Clin Endocrinol (Oxf). 1989;31:209–18.CrossRef
12.
Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1:129–35.PubMedCrossRef
13.
Haejin I, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209:170–9.e171–2.
14.
Abós D, Ruiz P, Prats E, et al. [Treatment of Graves-Basedow’s disease with 131I. Assessment of a “modulated fixed activity” protocol]. Rev Esp Med Nucl. 2007;26:3–10.PubMedCrossRef
15.
Adamali HI, Gibney J, O’Shea D, Casey M, McKenna TJ. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Ir J Med Sci. 2007;176:199–203.PubMedCrossRef
16.
Agarwal A, Mishra SK. Role of surgery in the management of Graves’ disease. J Indian Med Assoc. 2001;99:252, 254–6.
17.
Ahmad AM, Ahmad M, Young ET. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. Eur J Endocrinol. 2002;146:767–75.PubMedCrossRef
18.
Al-Kaabi JM, Hussein SS, Bukheit CS, Woodhouse NJ, Elshafie OT, Bererhi H. Radioactive iodine in the treatment of Graves’ disease. Saudi Med J. 2002;23:1049–53.PubMed
19.
Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87:1073–7.PubMedCrossRef
20.
Alfadda A, Malabu UH, El-Desouki MI, et al. Treatment of Graves’ hyperthyroidism—prognostic factors for outcome. Saudi Med J. 2007;28:225–30.PubMed
21.
Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism—prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86:3611–7.PubMedCrossRef
22.
Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12:399–405.PubMedCrossRef
23.
Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95:201–8.PubMedCrossRef
24.
Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid. 2011;21:647–54.PubMedCrossRef
25.
Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for graves’ disease. World J Surg. 2005;29:160–3.PubMedCrossRef
26.
Collier A, Ghosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens). 2009;8:273–8.
27.
Digonnet A, Willemse E, Dekeyser C, et al. Near total thyroidectomy is an optimal treatment for Graves’ disease. Eur Arch Otorhinolaryngol. 2010;267:955–60.PubMedCrossRef
28.
Dunkelmann S, Kuenstner H, Nabavi E, Rohde B, Groth P, Schuemichen C. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves’ disease. Eur J Nucl Med Mol Imaging. 2007;34:228–36.PubMedCrossRef
29.
Dunkelmann S, Kunstner H, Nabavi E, Eberlein U, Groth P, Schumichen C. Lithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Nuklearmedizin. 2006;45:213–8.PubMed
30.
Efremidou EI, Papageorgiou MS, Liratzopoulos N, Manolas KJ. The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can J Surg. 2009;52:39–44.PubMed
31.
El Refaei SM, Shawkat W. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves’ hyperthyroidism. Nucl Med Commun. 2008;29:642–8.PubMedCrossRef
32.
Eschmann SM, Thelen MH, Dittmann H, Bares R. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves’ disease: results of a prospective study. Exp Clin Endocrinol Diabetes. 2006;114:222–6.PubMedCrossRef
33.
Gaujoux S, Leenhardt L, Tresallet C, et al. Extensive thyroidectomy in Graves’ disease. J Am Coll Surg. 2006;202:868–73.PubMedCrossRef
34.
Grodski S, Stalberg P, Robinson BG, Delbridge LW. Surgery versus radioiodine therapy as definitive management for graves’ disease: the role of patient preference. Thyroid. 2007;17:157–60.PubMedCrossRef
35.
Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm. 2005;20:218–23.PubMedCrossRef
36.
Hao ST, Reasner CA 2nd, Becker RA. Use of cold iodine in patients with Graves’ disease: observations from a clinical practice. Endocr Pract. 2001;7:438–42.PubMed
37.
Hautzel H, Pisar E, Yazdan-Doust N, Schott M, Beu M, Muller HW. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. J Nucl Med. 2010;51:1917–22.PubMedCrossRef
38.
Hernandez-Jimenez S, Pachon-Burgos A, Aguilar-Salinas CA, et al. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage. Arch Med Res. 2007;38:185–9.PubMedCrossRef
39.
Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489–95.PubMedCrossRef
40.
Jensen BE, Bonnema SJ, Hegedus L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves’ disease. Eur J Endocrinol. 2005;153:15–21.PubMedCrossRef
41.
Kobe C, Eschner W, Sudbrock F, et al. Graves’ disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13–7.PubMed
42.
Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves’ disease and toxic nodular goitre? Eur J Nucl Med. 2001;28:1360–4.PubMedCrossRef
43.
Koyuncu A, Aydin C, Topcu O, Gokce ON, Elagoz S, Dokmetas HS. Could total thyroidectomy become the standard treatment for Graves’ disease? Surg Today. 2010;40:22–5.PubMedCrossRef
44.
Ku CF, Lo CY, Chan WF, Kung AW, Lam KS. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves’ disease. ANZ J Surg. 2005;75:528–31.PubMedCrossRef
45.
Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15:569–74.PubMedCrossRef
46.
Leow MK, Loh KC, Zhu M, Chan SP, Sundram FX. Iodine-131 therapy for hyperthyroidism prescribed by endocrinologist—our preliminary experience. Exp Clin Endocrinol Diabetes. 2009;117:616–21.PubMedCrossRef
47.
Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978–83.PubMedCrossRef
48.
Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168:1–4.PubMedCrossRef
49.
Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92:3547–52.PubMedCrossRef
50.
Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004;61:641–8.CrossRef
51.
Moreno P, Gomez JM, Gomez N, et al. Subtotal thyroidectomy: a reliable method to achieve euthyroidism in Graves’ disease. Prognostic factors. World J Surg. 2006;30:1950–6.CrossRef
52.
Muller PE, Bein B, Robens E, Bein HS, Spelsberg F. Thyroid surgery according to Enderlen-Hotz or Dunhill: a comparison of two surgical methods for the treatment of Graves’ disease. Int Surg. 2001;86:112–6.PubMed
53.
Nonchev BI, Terzieva DD, Dimov RS, Mateva NG, Tsvetkova TZ, Dimitrakov DY. Early hypothyroidism after subtotal thyroidectomy in patients with Graves’ disease—the role of the preoperative conservative treatment and hormonal status. Folia Med (Plovdiv). 2005;47:40–5.
54.
Okosieme OE, Chan D, Price SA, Lazarus JH, Premawardhana LD. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf). 2010;72:122–7.CrossRef
55.
Palestini N, Grivon M, Durando R, Freddi M, Odasso C, Robecchi A. Thyroidectomy for Graves’ hyperthyroidism. Retrospective study of patients’ appreciation. Ann Ital Chir. 2007;78:405–12.PubMed
56.
Panareo S, Rossi R, Fabbri S, et al. A practical method for the estimation of therapeutic activity in the treatment of Graves’ hyperthyroidism. Q J Nucl Med Mol Imaging. 2011;55:576–85.PubMed
57.
Pirnat E, Zaletel K, Gaberscek S, Fidler V, Hojker S. Early changes of thyroid hormone concentrations after (131)I therapy in Graves’ patients pretreated or not with methimazole. Nuklearmedizin. 2004;43:129–34.PubMed
58.
Razvi S, Basu A, McIntyre EA, Wahid ST, Bartholomew PH, Weaver JU. Low failure rate of fixed administered activity of 400 MBq 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun. 2004;25:675–82.PubMedCrossRef
59.
Regalbuto C, Marturano I, Condorelli A, Latina A, Pezzino V. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up. J Endocrinol Invest. 2009;32:134–8.PubMed
60.
Reinhardt MJ, Brink I, Joe AY, et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29:1118–24.PubMedCrossRef
61.
Robert J, Mariethoz S, Pache JC, et al. Short- and long-term results of total vs. subtotal thyroidectomies in the surgical treatment of Graves’ disease. Swiss Surg. 2001;7:20–4.PubMedCrossRef
62.
Sankar R, Sekhri T, Sripathy G, Walia RP, Jain SK. Radioactive iodine therapy in Graves’ hyperthyroidism: a prospective study from a tertiary referral centre in north India. J Assoc Physicians India. 2005;53:603–6.PubMed
63.
Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30.PubMedCrossRef
64.
Sanyal D, Mukhhopadhyay P, Pandit K, et al. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves’ disease. J Indian Med Assoc. 2008;106:360–1, 372.
65.
Schiavo M, Bagnara MC, Calamia I, et al. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves’ disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2011;34:201–5.PubMed
66.
Schneider P, Korber C, Korber-Hafner N, Hanscheid H, Reiners C. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves’ disease? Nuklearmedizin. 2002;41:240–4.PubMed
67.
Shi GM, Xu Q, Zhu CY, Yang YL. Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with Graves’ disease. J Int Med Res. 2009;37:576–82.PubMed
68.
Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H. Surgical management of Graves’ disease—10-year prospective trial at a single institution. Endocr J. 2008;55:161–7.PubMedCrossRef
69.
Takamura Y, Nakano K, Uruno T, et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy. Endocr J. 2003;50:595–601.PubMedCrossRef
70.
Vijayakumar V, Ali S, Nishino T, Nusynowitz M. What influences early hypothyroidism after radioiodine treatment for Graves’ hyperthyroidism? Clin Nucl Med. 2006;31:688–9.PubMedCrossRef
71.
Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730–7.PubMedCrossRef
72.
Wang RF, Tan J, Zhang GZ, Meng ZW, Zheng W. A comparative study of influential factors correlating with early and late hypothyroidism after (131)I therapy for Graves’ disease. Chin Med J (Engl). 2010;123:1528–2.
73.
Werga-Kjellman P, Zedenius J, Tallstedt L, Traisk F, Lundell G, Wallin G. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid. 2001;11:187–92.PubMedCrossRef
74.
Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34:1261–4.PubMedCrossRef
75.
Zantut-Wittmann DE, Ramos CD, Santos AO, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves’ disease. Nucl Med Commun. 2005;26:957–63.PubMedCrossRef
76.
Dionigi G, Dionigi R. Standardization of intraoperative neuromonitoring of recurrent laryngeal nerve in thyroid operation: to the editor. World J Surg. 2010;34:2794–5.PubMedCrossRef
77.
Palit TK, Miller CC, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res. 2000;90:161–5.PubMedCrossRef
78.
Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886–90.PubMedCrossRef
79.
Stålberg P, Svensson A, Hessman O, Akerström G, Hellman P. Surgical treatment of Graves’ disease: evidence-based approach. World J Surg. 2008;32:1269–77.PubMedCrossRef
80.
Chiapponi C, Stocker U, Mussack T, Gallwas J, Hallfeldt K, Ladurner R. The surgical treatment of Graves’ disease in children and adolescents. World J Surg. 2011;35:2428–31.PubMedCrossRef
Metadaten
Titel
What Is the Best Definitive Treatment for Graves’ Disease? A Systematic Review of the Existing Literature
verfasst von
Bradley M. Genovese, MD
Salem I. Noureldine, MD
Elizabeth M. Gleeson, BS, MPH
Ralph P. Tufano, MD, FACS
Emad Kandil, MD, FACS
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2606-x

Weitere Artikel der Ausgabe 2/2013

Annals of Surgical Oncology 2/2013 Zur Ausgabe

Palliative Care

Palliative Venting Gastrostomy in Patients with Malignant Bowel Obstruction and Ascites

Editorial

The Increasing Credibility of Sentinel Lymph Node Mapping in Endometrial Cancer

Pancreatic Tumors

Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies?

Pancreatic Tumors

Malignant Progression in IPMN: A Cohort Analysis of Patients Initially Selected for Resection or Observation

Hepatobiliary Tumors

Detection of Recurrences During Follow-up After Liver Surgery for Colorectal Metastases: Both Carcinoembryonic Antigen (CEA) and Imaging are Important

Gynecologic Oncology

Sentinel Node Biopsy Upstages Patients with Presumed Low- and Intermediate-risk Endometrial Cancer: Results of a Multicenter Study

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Traumatologische Notfälle Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise